Jing Huang Joins CareDx as Chief Data and AI Officer

CareDx Inc. has appointed Jing Huang Ph.D., as chief Data and Artificial Intelligence (AI) officer. Dr. Huang will lead key data science initiatives that are a part of the company’s long-term strategic growth plan.

Dr. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven track record in developing new products and solutions to advance patient care in the biopharmaceutical and diagnostics markets. In his newly-created role, Dr. Huang will help advance CareDx’s efforts to integrate data science methods and AI into its customer-facing products to enhance patient care and its internal business operations to improve efficiency and scalability.

“CareDx is a leader in introducing AI-enabled rejection risk prediction models, such as AlloView that incorporates AlloSure into the clinical management of kidney transplant patients,” CareDx President/CEO John W. Hanna said. “Our portfolio of solutions for transplant center management and patient clinical diagnosis generate a tremendous amount of utilization and genomic data that can be leveraged to build care models that further improve patient outcomes.”

Most recently, Dr. Huang was senior vice president of Bioinformatics and Data Science at Veracyte Inc. She also currently serves as president of the Bay Area Biotech-Pharma Statistical Workshop, is the founding president of DahShu, and is the Chapter Representative for the San Francisco Bay Area Chapter of the American Statistical Association.

Dr. Huang completed her doctorate in statistics from Stanford University. In 2023, she was elected as lifetime Fellow of the American Statistical Association in recognition of her contributions to the medical research community (in statistics) for numerous statistical innovations in genomic tests, and for exemplary leadership and community service to the profession.

“CareDx has been at the center of many innovations which have revolutionized the field of transplantation, and today sits on one of the industry’s largest pre- and post-transplant genomics and patient outcomes databases,” Dr. Huang commented. “I’m excited to leverage this dataset along with the rich public data on transplant utilization and outcomes to drive the next wave of innovation in transplant precision medicine.”

Headquartered in Brisbane, Calif., CareDx is a precision medicine solutions company that develops and commercializes clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and provides genomics-based information for transplant patients.